Inflammatory bowel disease patient concerns and experiences on transition to home-based infusions during the COVID-19 pandemic-Reference-Cited by-同舟云学术

Inflammatory bowel disease patient concerns and experiences on transition to home-based infusions during the COVID-19 pandemic

Published:2022-12 Issue:12 Volume:18 Page:4138-4143
ISSN:1551-7411
Container-title:Research in Social and Administrative Pharmacy
language:en
Short-container-title:Research in Social and Administrative Pharmacy

Author:

Jacob Janson,Aintabi Daniel,DeJonckheere Melissa^ORCID,Cohen-Mekelburg Shirley A.^ORCID,Allen John I.,Irani David N.,Fendrick A. Mark,Waljee Akbar K.,Higgins Peter D.R.,Berinstein Jeffrey A.^ORCID

Publisher

Elsevier BV

Subject

Pharmaceutical Science,Pharmacy

Reference13 articles.

1. Home infliximab infusions are associated with suboptimal outcomes without cost savings in inflammatory bowel diseases;Giese-Kim;Am J Gastroenterol,2020

2. Home vs hospital infusion of biologic agents for patients with inflammatory bowel diseases;Fenster;Clin Gastroenterol Hepatol,2020

3. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: a stepwise, safety and patient-orientated process towards sustainability;Bohra;World J Gastroenterol,2020

4. A home infliximab infusion program;Condino;J Pediatr Gastroenterol Nutr,2005

5. Short article: remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease;Kuin;Eur J Gastroenterol Hepatol,2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions;Inflammatory Bowel Diseases;2023-10-11

2. Home-based Biologic Infusions for Inflammatory Bowel Disease: Are We Ready for Prime Time?;Inflammatory Bowel Diseases;2023-10-11